Randomized trial evaluates enhanced antimalarial activity in heterocyclic compounds, suggesting new treatment options.
analogues. Molecular docking confirmed favourable interactions with Plasmodium falciparum-dihydrofolate reductase, and all the hit compounds were found to be non-hemolytic. These findings highlight the effectiveness of heterocyclic scaffold modification in enhancing antiplasmodial activity and demonstrate the potential of morpholine-based triazene-chalcones as promising antimalarial agents.
No takes yet. Share an insight, caveat, or question.
Thottasseri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: